Non-Current Assets
Equity securities
Boston Scientific Equity securities decreased by 5.9% to $16.00M in Q1 2026 compared to the prior quarter. Over 2 years (FY 2020 to FY 2025), Equity securities shows a downward trend with a -79.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ4 2024
Last reportedQ1 2026
How to read this metric
An increase reflects positive market performance of the underlying investments or additional capital deployment into equities.
Detailed definition
This represents the fair market value of the company's investment portfolio consisting of equity securities in other ent...
Peer comparison
Standard for companies with large corporate venture arms or significant treasury investment portfolios.
Metric ID:
ins_equity_securitiesHistorical Data
8 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $176.00M | $4.00M | $10.00M | $8.00M | $5.00M | $3.00M | $17.00M | $16.00M |
| QoQ Change | — | -97.7% | +150.0% | -20.0% | -37.5% | -40.0% | +466.7% | -5.9% |
| YoY Change | — | — | — | — | -97.2% | -25.0% | — | — |
Range$3.00M – $176.00M
CAGR-74.6%
Avg YoY Growth-61.1%
Median YoY Growth-61.1%
Equity securities at Other Companies
Frequently Asked Questions
- What is Boston Scientific's equity securities?
- Boston Scientific (BSX) reported equity securities of $16.00M in Q1 2026.
- What is the long-term trend for Boston Scientific's equity securities?
- Over 2 years (2020 to 2025), Boston Scientific's equity securities has grown at a -79.7% compound annual growth rate (CAGR), from $414.00M to $17.00M.
- What does equity securities mean?
- The current market value of the company's stock investments in other businesses.